Nonetheless, the results of our study highlight an increased risk of ILD associated with ALK TKIs for the treatment of NSCLC and provide a better basis for understanding potential ILD associated with ALK TKIs, which helps clinicians pay attention to risk management. The gene discussed is ALK; the disease is interstitial lung disease.